## Jianchun Zhao

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2980868/publications.pdf

Version: 2024-02-01

1478505 1474206 11 84 9 6 citations h-index g-index papers 11 11 11 115 docs citations times ranked citing authors all docs

| #  | Article  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Development and validation of LCâ€MS/MS method for amlexanox in rat plasma and its application in preclinical pharmacokinetics. Biomedical Chromatography, 2021, , e5288.  | 1.7 | 1         |
| 2  | Combination of a novel microtubule inhibitor MBRI-001 and gemcitabine synergistically induces cell apoptosis by increasing DNA damage in pancreatic cancer cell lines. Investigational New Drugs, 2020, 38, 1207-1217. | 2.6 | 4         |
| 3  | Design, synthesis, and biological evaluation of novel stachydrine derivatives as potent neuroprotective agents for cerebral ischemic stroke. Naunyn-Schmiedeberg's Archives of Pharmacology, 2020, 393, 2529-2542.     | 3.0 | 6         |
| 4  | Structure-based design and synthesis of novel furan-diketopiperazine-type derivatives as potent microtubule inhibitors for treating cancer. Bioorganic and Medicinal Chemistry, 2020, 28, 115435.                      | 3.0 | 12        |
| 5  | Development of M10, myricetin-3-O- $\hat{l}^2$ -d-lactose sodium salt, a derivative of myricetin as a potent agent of anti-chronic colonic inflammation. European Journal of Medicinal Chemistry, 2019, 174, 9-15.     | 5.5 | 19        |
| 6  | Synthesis of deuterium-enriched sorafenib derivatives and evaluation of their biological activities. Molecular Diversity, 2019, 23, 341-350.   | 3.9 | 11        |
| 7  | Antitumor activity of the microtubule inhibitor MBRI-001 against human hepatocellular carcinoma as monotherapy or in combination with sorafenib. Cancer Chemotherapy and Pharmacology, 2018, 81, 853-862.              | 2.3 | 8         |
| 8  | In vitro and in vivo pharmacokinetic and pharmacodynamic study of MBRI-001, a deuterium-substituted plinabulin derivative as a potent anti-cancer agent. Bioorganic and Medicinal Chemistry, 2018, 26, 4687-4692.      | 3.0 | 6         |
| 9  | Development of MBRI-001, a deuterium-substituted plinabulin derivative as a potent anti-cancer agent.<br>Bioorganic and Medicinal Chemistry Letters, 2017, 27, 1416-1419.  | 2.2 | 16        |
| 10 | Synthesis and pharmacokinetic property improvement of deuterated plinabulin 9. Journal of Ocean University of China, 2017, 16, 305-310.  | 1.2 | 1         |
| 11 | Design, synthesis, and biological evaluation of catalpalactone and its analogs. Medicinal Chemistry Research, 0, , $1.$  | 2.4 | O         |